Skip to main content
Clinical Trials/NCT02061657
NCT02061657
Completed
Phase 3

Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations

Ain Shams University1 site in 1 country50 target enrollmentJune 2013

Overview

Phase
Phase 3
Intervention
Misoprostol
Conditions
Leiomyoma
Sponsor
Ain Shams University
Enrollment
50
Locations
1
Primary Endpoint
intraoperative blood loss
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The aim of this research work is to assess the effect of using single preoperative dose of rectal misoprostol in abdominal myomectomy operations on blood loss, duration of the operation and possible operative complications

Detailed Description

This study is a randomized, double-blind, controlled study that will be conducted in Ain Shams University Maternity Hospital. A total of 50 women scheduled to undergo myomectomy for symptomatic uterine myoma will be included in this study after taking their consent for this clinical trial after full explanation of the trial. The total of 50 included patients will be divided into two groups: Group A (Study group;): will Include 25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.Group B (Control group): will Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
July 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr.Ahmed Elnaggar

DR

Ain Shams University

Eligibility Criteria

Inclusion Criteria

  • Premenopausal patients aged between 35 to 50 years old.
  • Five or less symptomatic uterine myomas .
  • Maximum diameter of the largest myoma is 6 cm .
  • All myomas are subserous or intramural.
  • Uterine size less than 24 weeks pregnancy

Exclusion Criteria

  • History of previous surgery.
  • Allergy to Misoprostol.
  • Hypertension.
  • Cardiac and Pulmonary diseases.
  • Patients who have bleeding disorders.
  • Anemia (Hb \< 10g %).
  • Chronic endocrine or metabolic diseases such as Diabetes.
  • Obesity (body mass index \> 30 kg/m2).
  • Cases that will require intraoperative conversion of myomectomy to hysterectomy.

Arms & Interventions

Myomectomy, rectal Misoprostol

25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.

Intervention: Misoprostol

Myomectomy, Placebo

Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.

Intervention: Placebo( for misoprostol)

Outcomes

Primary Outcomes

intraoperative blood loss

Time Frame: time from peritoneum opening till its closure around (1 Hour)

Study Sites (1)

Loading locations...

Similar Trials